高强度聚焦超声对中晚期前列腺癌患者去势治疗后机体免疫指标的影响

doi:10.3969/j.issn.1007-3969.2014.12.007

中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (12): 920-924.doi: 10.3969/j.issn.1007-3969.2014.12.007

高强度聚焦超声对中晚期前列腺癌患者去势治疗后机体免疫指标的影响

吴同胜¹　谭卫林²　肖平¹　付俊¹　吴云²

1. 上海建工医院泌尿科，上海 200083 ；
2. 上海建工医院高强度聚焦超声治疗室，上海 200083

出版日期:2014-12-30 发布日期:2015-05-07
通信作者: 谭卫林　E-mail:weilin_tan@msn.com
基金资助:
上海市虹口区科委科研课题(虹卫1102-19)。

High intensity focused ultrasound affect the body anti-tumor immune indexes of intermediate and advanced prostate cancer patients after castration

WU Tong-sheng¹, TAN Wei-lin², XIAO Ping¹, FU Jun¹, WU Yun²

1.Department of Urology, Shanghai Jian-gong Hospital, Shanghai 200083, China; 2. High Intensity Focused Ultrasound Room, Shanghai Jian-gong Hospital, Shanghai 200083, China

Published:2014-12-30 Online:2015-05-07
Contact: TAN Wei-lin E-mail: weilin_tan@msn.com

摘要/Abstract

摘要： 背景与目的：高强度聚焦超声(high intensity focused ultrasound，HIFU)可以有效治疗前列腺癌，但肿瘤是一种全身性的疾病，理想的肿瘤治疗方法是能够在不损伤正常组织的同时进行局部肿瘤切除，还能够激活全身的抗肿瘤免疫反应。本研究旨在探讨HIFU治疗对去势治疗后中晚期前列腺癌患者机体免疫指标的影响。方法：行去势治疗的中晚期前列腺癌患者40例，随机分为2组，HIFU组为去势治疗后2周行HIFU治疗(n=20)，对照组为单纯去势治疗(n=20)，全部经直肠前列腺穿刺病理检查确诊，均为晚期前列腺癌患者，即前列腺特异性抗原(prostate specific antigen，PSA)>20 ng/mL。患者自愿接受HIFU治疗并签署知情同意书。HIFU组与对照组患者平均年龄(72.56±12.38)岁、(75.23±9.35)岁(P=0.446 3)；初始PSA为(105.22±20.55)ng/mL、(100.53±18.38)ng/mL(P=0.451 5)。分别取治疗前和治疗后2周前列腺癌患者外周血6 d，检测T淋巴细胞亚群(CD4⁺、CD8⁺、CD4⁺/CD8⁺)和外周血Th细胞因子(IFN-γ、IL-2、IL-4、IL-10)。结果：HIFU组患者治疗后CD4⁺百分比及CD4⁺/CD8⁺比值明显升高；细胞因子IFN-γ、IL-2水平明显增高，而IL-4、IL-10水平明显降低，与治疗前相比差异有统计学意义(P＜0.05)，Th1/Th2平衡向Th1漂移。而对照组患者治疗前、后各项免疫指标差异无统计学意义(P＞0.05)。HIFU组与对照组前、后各项免疫指标差值比较差异有统计学意义(P＜0.05)。结论：HIFU治疗可在近期内改善去势治疗后中晚期前列腺癌患者机体免疫功能。

关键词: 高强度聚焦超声, 前列腺癌, 免疫学

Abstract: Background and purpose: High intensity focused ultrasound (HIFU) can be effective in the treatment of prostate cancer, however cancer is a systemic disease, the treatment method is not only resect local tumor in no damage to normal tissue but also activate the body’s anti- tumor immune response. This paper aimd to explore the effect of HIFU treatment on the body anti-tumor immunity of intermediate and advanced prostate cancer patients after castration. Methods: Forty patients with intermediate and advanced prostate cancer were randomly divided into 2 groups. Twenty were treated by HIFU after 2 weeks through castration and the other 20 had sole castration as control group, all patients diagnosed by transrectal prostate biopsy pathology and identified as advanced prostate cancer, prostate specific antigen (PSA)>20 ng/mL. Patients accepted the HIFU therapy and signed the informed consent. The average ages of HIFU and the control group patients were (72.56+12.38) and (75.23+9.35) years old (P=0.446 3) and the mean levels of initial PSA were (105.22+20.55)ng/mL and (100.53+18.38)ng/mL (P=0.451 5). We collected the venous blood before and after all treatment in the intervals of 2 weeks. Test items included T lymphocyte (CD4⁺, CD8⁺, CD4⁺/CD8⁺) and Th cell factor (IFN-γ, IL-2, IL-4, IFN- IL-10). Results: In the HIFU-treated patients, the percentage of CD4⁺ and CD4⁺/CD8⁺ ratio increased significantly after treatment; IFN-γ, IL-2 were significantly increased, while IL-4 and IL-10 were decreased significantly, the difference was statistically significant (P<0.05), Th1/Th2 balanced to Th1 drift. The control group had no significant difference in each index between before and after treatments (P>0.05). HIFU treatment group had significant difference in each index between before and after treatments (P<0.05). Conclusion: HIFU treatment can improve the body anti-tumor immunity of intermediate and advanced prostate cancer patients after castration.

Key words: High intensity focused ultrasound, Prostate cancer, Immunology

吴同胜,谭卫林,肖平等. 高强度聚焦超声对中晚期前列腺癌患者去势治疗后机体免疫指标的影响[J]. 中国癌症杂志, 2014, 24(12): 920-924.

WU Tong-sheng, TAN Wei-lin, XIAO Ping et al. High intensity focused ultrasound affect the body anti-tumor immune indexes of intermediate and advanced prostate cancer patients after castration[J]. China Oncology, 2014, 24(12): 920-924.

[1]	徐文浩, 田熙, 艾合太木江·安外尔, 瞿元元, 施国海, 张海梁, 叶定伟. 人工智能在泌尿系统肿瘤中的应用研究进展[J]. 中国癌症杂志, 2022, 32(1): 68-74.
[2]	韦　煜, 张挺维, 何　屹, 李　俊, 毕建斌, 曾　宇, 万里军, 吴高亮, 王焕昇, 张　军, 朱　崴, 瞿元元, 朱　耀, 叶定伟 . 氟唑帕利治疗转移性去势抵抗性前列腺癌的初步有效性及安全性研究[J]. 中国癌症杂志, 2021, 31(7): 561-566.
[3]	曹达龙, 朱文恺, 施国海, 张海梁, 王子良, 叶定伟. PRUNE2点突变影响前列腺癌DU145细胞增殖、凋亡、侵袭和迁移[J]. 中国癌症杂志, 2021, 31(6): 441-446.
[4]	王　铸, 张　颖, 张建文, 邓　琼, 梁　辉. 核受体HNF4α通过调控雄激素受体表达促进去势抵抗性前列腺癌进展[J]. 中国癌症杂志, 2021, 31(3): 170-175.
[5]	卞晓洁, 叶定伟. 前列腺癌雄激素剥夺治疗的新思路——睾酮最大控制临床研究新进展[J]. 中国癌症杂志, 2021, 31(12): 1209-1214.
[6]	潘　剑, 韦　煜, 叶定伟, 朱　耀. EGFR（rs884419）基因多态性与前列腺癌临床病理学特征的相关性分析[J]. 中国癌症杂志, 2021, 31(11): 1104-1109.
[7]	潘　剑, 韦　煜, 吴俊龙, 万方宁, 叶定伟, 朱　耀. HSD3B1基因多态性与前列腺癌临床病理学特征的相关性分析[J]. 中国癌症杂志, 2020, 30(9): 650-655.
[8]	樊　博, 齐　盼, 苏建志, 卫书飞, 张　轩, 张爱莉 . 河北医科大学第四医院前列腺癌患者的基线特征与生存分析[J]. 中国癌症杂志, 2020, 30(8): 620-625.
[9]	中国抗癌协会泌尿男生殖系肿瘤专业委员会, 中国临床肿瘤学会前列腺癌专家委员会. 中国前列腺癌患者基因检测专家共识（2020年版）[J]. 中国癌症杂志, 2020, 30(7): 551-560.
[10]	徐耀宗, 顾　晓, 王　飞, 栾　阳, 卢圣铭, 黄天宝, 丁雪飞 . 术前低PSA的Gleason 8~10分前列腺癌患者临床特点[J]. 中国癌症杂志, 2020, 30(5): 383-387.
[11]	李　曾, 廖　洪, 毛　顿, 吴　毅, 肖英明, 杨盛柯, 钟　磊, 周术奎, 陈勇吉. ¹⁸ F-PSMA-1007 PET/CT在初诊前列腺癌精准评估中的价值及对临床治疗决策的影响[J]. 中国癌症杂志, 2020, 30(3): 231-236.
[12]	周　舰, 张朝阳, 孙　伟, 杨　军, 张志超, 戚晓红. miR-503靶向TLR4对前列腺癌多西他赛耐药的影响[J]. 中国癌症杂志, 2020, 30(11): 858-864.
[13]	王宝华, 沙宇婷, 何凤蝶, 吴　静. 前列腺特异性抗原对中国人群前列腺癌早期检测价值的Meta分析[J]. 中国癌症杂志, 2020, 30(11): 879-886.
[14]	陈?阳,阳青松,陆建平 . DWI单、双指数模型对中央腺体前列腺癌及良性前列腺增生的鉴别诊断价值[J]. 中国癌症杂志, 2019, 29(8): 583-589.
[15]	张能，苏鹏，陈书练，李晓光，黄翔，罗旭. 前列腺癌中锌指蛋白ZIC2表达及对细胞增殖和凋亡的影响[J]. 中国癌症杂志, 2019, 29(4): 250-256.

高强度聚焦超声对中晚期前列腺癌患者去势治疗后机体免疫指标的影响

High intensity focused ultrasound affect the body anti-tumor immune indexes of intermediate and advanced prostate cancer patients after castration

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价